SIC
TVRD

SJS Investment Consulting’s Tvardi Therapeutics TVRD Stock Holding History

SJS Investment Consulting’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Hold
1
– – ﹤0.01% 2884
2026
Q1 		$4 Buy
+1
New +$4 ﹤0.01% 2461
2023
Q2 		– Sell
-8
Closed -$1.47K – 1628
2023
Q1 		$1.47K Hold
8
– – ﹤0.01% 713
2022
Q4 		$3.22K Hold
8
– – ﹤0.01% 455
2022
Q3 		$3K Buy
+8
New +$2.9K ﹤0.01% 412
2022
Q1 		$4K Hold
8
– – ﹤0.01% 469
2021
Q4 		$4K Buy
+8
New +$4.02K ﹤0.01% 448

Other funds holding TVRD

DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

SJS Investment Consulting's TVRD Position: Q2 2026 in Review

SJS Investment Consulting held its Tvardi Therapeutics (TVRD) position steady in Q2 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #2884.

SJS Investment Consulting first reported a position in TVRD in Q4 2021 and has held it in 7 quarters since. The position peaked at $4K in Q1 2022. 12 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • SJS Investment Consulting held 1 share of Tvardi Therapeutics worth $2 as of Q2 2026.
  • SJS Investment Consulting left its Tvardi Therapeutics share count unchanged in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2884 holding.
  • SJS Investment Consulting first reported a position in Tvardi Therapeutics in Q4 2021 and has held it in 7 quarters since.
  • SJS Investment Consulting's Tvardi Therapeutics position peaked at $4K in Q1 2022.
  • 12 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.